Esophageal Cancer Clinical Trials

The purpose of this study is to find the highest dose of the investigational drug AVA6000 that can be given safely in people with advanced solid tumors that are not responding to treatment. AVA6000 is very similar to a standard chemotherapy drug called doxorubicin. Like doxorubicin, AVA6000 works to slow or stop the growth of cancer cells by blocking an enzyme. Unlike doxorubicin, however, AVA6000 is a "prodrug," meaning it remains inactive until it reaches the site of the cancer. Because of the way AVA6000 works, it may be useful for treating cancer with fewer side effects than doxorubicin. AVA6000 is given intravenously (by vein).

Researchers are assessing different doses of CHS-114 when combined with toripalimab in people with advanced digestive cancers. The people in this study have digestive cancers that have metastasized (spread) or are inoperable (cannot be surgically removed). These cancers include:

Researchers want to find the best dose of ZL-1310 to use in people with advanced digestive tumors. The people in this study have gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) that spread and keeps growing after treatment. These tumors include NEC of the esophagus, stomach, pancreas, gallbladder, or colon/rectum.

Researchers are assessing a combination of medications to see if they work well against upper digestive cancers. The people in this study have esophagus, stomach, or gastro-esophageal junction cancers that spread and keep growing after treatment.

Researchers want to see if combining AZD0901 and rilvegostomig with standard chemotherapy works well in people with gastric or gastroesophageal junction (GEJ) cancer. GEJ cancer occurs where the esophagus joins the stomach.

Researchers are assessing the use of multiple medications given before surgery to treat esophagogastric cancers. The people in this study have esophagus, stomach, or gastro-esophageal junction cancers that can be taken out (operable). In addition, their cancers make a protein called HER2.

Researchers are comparing AZD0901 with standard treatments in people with advanced gastric cancer. The people in this study have cancer of the stomach or the junction between the esophagus and stomach (gastroesophageal junction). The people in this study have cancers that make a protein called Claudin18.2 (CLDN18.2).

Researchers are comparing several combination drug treatments for people with cancer of the stomach or gastroesophageal junction (GEJ). The people in this study have gastric or GEJ cancer that metastasized (spread) or is inoperable (cannot be surgically removed). In addition, their tumors make a protein called HER2.

The purpose of this study is to find the highest dose of the investigational immunotherapy drug TJ033721 that can be given safely in people with advanced cancers of the pancreas, esophagus, stomach, or junction between the esophagus and stomach. TJ033721 is an antibody that binds to Claudin 18.2, a protein expressed on some cancers cells, and to 4-1BB, a protein found on immune cells. TJ033721 may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. It is given intravenously (by vein).

Trastuzumab is an anticancer medication that targets HER2, a protein overproduced by some cancers of the stomach (gastric cancers) and the junction between the stomach and esophagus (gastro-esophageal junction or GEJ cancers). In this study, researchers are evaluating the safety of combining the drug trastuzumab deruxtecan (T-DXd) with immunotherapy and/or chemotherapy in patients with inoperable or metastatic stomach and GEJ cancers that have come back or continued to grow despite prior treatment.